PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
In head and neck squamous cell carcinoma (HNSCC), data from studies using checkpoint-inhibiting antibodies that target programmed death 1 (PD-1) or its ligand the programmed death ligand 1 (PD-L1) demonstrated outstanding clinical activity. Translational investigations also suggested some correlatio...
Main Authors: | D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1844403 |
Similar Items
-
Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
by: Yixiao Qin, et al.
Published: (2021-03-01) -
Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs
by: Simin Ahmadvand, et al.
Published: (2024-01-01) -
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma
by: Ayman Oweida, et al.
Published: (2017-10-01) -
Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma
by: Adam Khorasanchi, et al.
Published: (2022-10-01) -
Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
by: Jong Chul Park, et al.
Published: (2022-06-01)